Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
EQRX EQRx	$2.34	$2.29	$1.58 ▼ $5.55	$1.14B	0.48	3.30 million shs	N/A
KNSA Kiniksa Pharmaceuticals International	$29.06 +1.2%	$26.31	$17.38 ▼ $30.69	$2.10B	0.06	516,316 shs	655,828 shs
MIRM Mirum Pharmaceuticals	$51.11 +1.7%	$44.77	$32.34 ▼ $54.23	$2.49B	0.95	474,489 shs	310,000 shs
SAGE Sage Therapeutics	$9.22 -0.9%	$7.27	$4.62 ▼ $13.47	$582.37M	0.18	1.27 million shs	1.29 million shs

20 High-Yield Dividend Stocks that Could Ruin Your Retirement

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
EQRX EQRx	0.00%	0.00%	0.00%	0.00%	0.00%
KNSA Kiniksa Pharmaceuticals International	+1.18%	+3.97%	+8.07%	+27.68%	+54.00%
MIRM Mirum Pharmaceuticals	+1.65%	+0.81%	+16.16%	+10.44%	+46.66%
SAGE Sage Therapeutics	-0.86%	+1.10%	+41.19%	+7.21%	-20.24%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
EQRX EQRx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	3.2068 of 5 stars	3.5	3.0	0.0	0.0	2.5	3.3	0.6
MIRM Mirum Pharmaceuticals	3.9347 of 5 stars	3.6	1.0	0.0	4.2	2.6	1.7	0.6
SAGE Sage Therapeutics	3.0135 of 5 stars	2.0	1.0	0.0	4.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
EQRX EQRx	0.00	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$38.80	33.52% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	28.15% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-3.11% Downside

Current Analyst Ratings Breakdown

Latest KNSA, EQRX, MIRM, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$73.00 ➝ $77.00
5/9/2025	MIRM Mirum Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$74.00 ➝ $76.00
4/29/2025	KNSA Kiniksa Pharmaceuticals International	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00

(Data available from 6/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
EQRX EQRx	N/A	N/A	N/A	N/A	$2.40 per share	N/A
KNSA Kiniksa Pharmaceuticals International	$423.24M	5.01	N/A	N/A	$6.60 per share	4.40
MIRM Mirum Pharmaceuticals	$336.89M	7.51	N/A	N/A	$4.70 per share	10.87
SAGE Sage Therapeutics	$41.24M	14.00	N/A	N/A	$7.60 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
EQRX EQRx	-$169.09M	-$0.55	N/A	∞	N/A	N/A	-20.33%	-19.32%	N/A
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	116.24	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	N/A	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)

Latest KNSA, EQRX, MIRM, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
EQRX EQRx	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
EQRX EQRx	N/A	18.77	22.60
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
SAGE Sage Therapeutics	N/A	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
EQRX EQRx	72.33%
KNSA Kiniksa Pharmaceuticals International	53.95%
MIRM Mirum Pharmaceuticals	N/A
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
EQRX EQRx	18.30%
KNSA Kiniksa Pharmaceuticals International	53.48%
MIRM Mirum Pharmaceuticals	22.87%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
EQRX EQRx	362	487.42 million	398.22 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	38.21 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

KNSA, EQRX, MIRM, and SAGE Headlines

Recent News About These Companies

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

June 23 at 8:36 AM | msn.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23 at 7:59 AM | globenewswire.com

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

June 22 at 8:25 PM | msn.com

Robert W. Baird Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 21, 2025 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Given New $9.00 Price Target at Robert W. Baird

June 20, 2025 | marketbeat.com

Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more

June 20, 2025 | mmm-online.com

Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to Hold at Piper Sandler

June 19, 2025 | americanbankingnews.com

Truist Financial Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 19, 2025 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright

June 19, 2025 | americanbankingnews.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

June 18, 2025 | biospace.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $8.50 at Canaccord Genuity Group

June 18, 2025 | americanbankingnews.com

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

June 17, 2025 | zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

June 17, 2025 | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from Piper Sandler

June 17, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $9.00

June 17, 2025 | marketbeat.com

HC Wainwright Reaffirms "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE)

June 17, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

June 17, 2025 | accessnewswire.com

Sage Therapeutics (NASDAQ:SAGE) Given New $8.50 Price Target at Canaccord Genuity Group

June 17, 2025 | marketbeat.com

After rebuffing Biogen, Sage pairs off with Supernus

June 17, 2025 | pharmaphorum.com

Supernus makes depression drug play with $795m Sage buyout

June 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KNSA, EQRX, MIRM, and SAGE Company Descriptions

EQRx NASDAQ:EQRX

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's clinical programs in pipeline includes Aumolertinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); Sugemalimab, is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody that treats stage III and stage IV NSCLC; and Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which has completed Phase 1 clinical trial in patients with metastatic breast cancer, as well as in combination with other targeted therapies for the treatment of patients with hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer. Its other programs in pipeline comprises clinical and pre-clinical, and discovery stage assets, such as Nofazinlimab, an anti-programmed death-1 (PD-1) antibody that is in Phase 3 trial for the treatment of patients with primary liver cancer, and for the treatment of patients with hepatocellular carcinoma; and EQ121, a selective Janus kinase-1 (JAK-1) inhibitor that has completed Phase 1 and in various Phase 1b and 2 trials in for the treatment of ankylosing spondylitis, atopic dermatitis, and rheumatoid arthritis. EQRx, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts. As of November 9, 2023, EQRx, Inc. operates as a subsidiary of Revolution Medicines, Inc.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$29.06 +0.34 (+1.18%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$29.04 -0.01 (-0.05%)

As of 08:00 AM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Mirum Pharmaceuticals NASDAQ:MIRM

$51.11 +0.83 (+1.65%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$49.82 -1.30 (-2.53%)

As of 07:11 AM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Sage Therapeutics NASDAQ:SAGE

$9.22 -0.08 (-0.86%)

Closing price 06/24/2025 04:00 PM Eastern

Extended Trading

$9.18 -0.04 (-0.39%)

As of 07:00 AM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time